Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EBP | Q15125 | 5/20 | 0.40 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119445 | 0.91 | EPHX2 (0.49) | EPHX2MEN1MAPK1KMT2AEBP | |
| SCHEMBL5125598 | 0.87 | EPHX2 (0.49) | EPHX2 | |
| SCHEMBL4111436 | 0.86 | BDKRB1 (0.41) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5132127 | 0.81 | EPHX2 (0.46) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5123711 | 0.81 | EPHX2 (0.53) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5131915 | 0.80 | GRIN2B (0.42) | EPHX2EBPDHCR7 | |
| SCHEMBL4123581 | 0.80 | NPSR1 (0.44) | MEN1KMT2A | |
| SCHEMBL5125788 | 0.78 | MEN1 (0.40) | MEN1MAPK1KMT2A | |
| SCHEMBL5085809 | 0.78 | TSHR (0.54) | EPHX2MEN1KMT2A | |
| SCHEMBL5122649 | 0.76 | ALDH1A1 (0.54) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | EPHX2 1287/4885MEN1 1340/4885MAPK1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.